Class Action Filed Against Pacira BioSciences, Inc. (PCRX) Seeking Recovery for Investors - Contact Levi & Korsinsky ...

Pacira BioSciences, Inc. Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm ...

PCRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! ...

Lawsuit Overview - Pacira BioSciences and certain executives are charged with failing to disclose material information during the Class Period, violating federal securities laws [3] - The lawsuit is pending in the United States District Court for the District of New Jersey [1] Key Events - On August 9, 2024, Pacira released results of its lawsuit against eVenus for patent infringement related to Exparel, which accounts for approximately 80% of the company's revenue [4] - The U S District Court for the District of New Jersey found that Pacira's U S Patent No 11,033,495 is not valid, meaning eVenus was not infringing on anything [4] - Following this news, Pacira's share price fell over 47%, from $22 36 per share on August 8, 2024 to a low of $11 70 per share on August 9, 2024 [5] Legal Actions - Investors who purchased Pacira securities between August 2, 2023 and August 8, 2024 have until March 14, 2025 to file lead plaintiff applications in the securities class action lawsuit [1] - The case is titled Alvarez v Pacira BioSciences, Inc, et al, No 25-cv-00322 [5]

Pacira BioSciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – PCRX ...

Core Viewpoint - A class action lawsuit has been filed against Pacira BioSciences, Inc. for allegedly failing to disclose insufficient patent protection for its key product, Exparel, which significantly impacted its stock value [1][2][3]. Group 1: Allegations and Impact - The lawsuit claims that Pacira misled investors about the strength of its patent protections for Exparel, which is crucial for the company's growth and revenue [2][3]. - The '495 patent, which was believed to protect Exparel, was invalidated in a court ruling, leading to concerns that generic versions could enter the market, jeopardizing approximately 80% of Pacira's revenue [3]. - Following the announcement of the patent loss on August 9, 2024, Pacira's stock price plummeted from $22.36 to $11.70, a decline of over 47% in one day [3]. Group 2: Class Action Participation - Investors who purchased Pacira securities between August 2, 2023, and August 8, 2024, may be eligible to participate in the class action [1][4]. - Shareholders interested in serving as lead plaintiffs must submit their applications by March 14, 2025, but participation is not required to be eligible for recovery [4]. Group 3: Company Background - Pacira BioSciences, Inc. is an American pharmaceutical company focused on developing non-opioid pain management and regenerative health solutions [1].

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira BioSciences, Inc. Lawsuit - PCRX ...

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PCRX ...

Shareholders of Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX ...

PCRX LAWSUIT ALERT: Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline ...